会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • SINGLE VARIABLE DOMAINS AGAINST THE NOTCH PATHWAYS
    • 唯一可变的域名对Notch路径
    • WO2009124931A8
    • 2010-11-18
    • PCT/EP2009054139
    • 2009-04-07
    • ABLYNX NVSAUNDERS MICHAEL JOHN SCOTTDE HAARD JOHANNES JOSEPH WILHELMUSDOLK EDWARDDE BRUIN RENEEVANLANDSCHOOT PETER
    • SAUNDERS MICHAEL JOHN SCOTTDE HAARD JOHANNES JOSEPH WILHELMUSDOLK EDWARDDE BRUIN RENEEVANLANDSCHOOT PETER
    • C07K16/28
    • C07K16/28C07K16/2896C07K2317/22C07K2317/569C07K2317/76
    • The present invention relates to amino acid sequences (also referred to herein as "single variable domain(s) of the invention", "NanobodyTM of the invention" or "NanobodiesTM of the invention ", ilpolypeptide(s) of the invention") that are directed against (as defined herein) members of the Notch signalling pathway such as the four mammalian members of the Notch Receptors (Notch-1, Notch-2, Notch-3, Notch-4, hereinafter also "Notch Receptors") and the five mammalian members of the Notch Ligands (the Delta-like family with "DLL1", "DLL3", "DLL4" wherein "DLL" stands for Delta-like ligand; the Jagged family with "Jagged-1", "Jagged-2", hereinafter also "Notch Ligands"), as well as to constructs that comprise or essentially consist of one or more such single variable domain(s) (also referred to herein as "construct of the invention " and "constructs of the invention", "NanobodyTM of the invention " or "NanobodiesTM of the invention",, respectively). In particular, this invention relates to Notch pathway interfering single variable domains down- or up-regulating Notch signaling (also referred to herein as "Notch-antagonists" or "Notch-agonists").
    • 本发明涉及本发明的氨基酸序列(本文中也称为“本发明的单可变结构域”,“本发明的纳米抗体TM”或“本发明的纳米抗体”,本发明的多肽)“) 针对(如本文所定义)Notch信号传导途径的成员,例如Notch受体(Notch-1,Notch-2,Notch-3,Notch-4,以下也称为“Notch受体”)的四种哺乳动物成员和 Notch Ligands的五个哺乳动物成员(具有“DLL1”,“DLL3”,“DLL4”的三角形家族,其中“DLL”代表三角形配体;具有“Jagged-1”,“Jagged-2” “,以下也称为”Notch Ligands“),以及包含或基本上由一个或多个这样的单可变结构域(本文中也称为”本发明的构建体“和”本发明的构建体“)构成的构建体, ,“本发明的纳米抗体TM”或“本发明的纳米抗体TM”),特别地,本发明涉及 o Notch途径干扰单可变区下调或上调Notch信号传导(本文中也称为“Notch-拮抗剂”或“Notch-激动剂”)。
    • 6. 发明申请
    • AMINO ACID SEQUENCES DIRECTED AGAINST THE NOTCH PATHWAYS AND USES THEREOF
    • 针对麻雀路径的氨基酸序列及其用途
    • WO2009124931A2
    • 2009-10-15
    • PCT/EP2009054139
    • 2009-04-07
    • ABLYNX NVSAUNDERS MICHAEL JOHN SCOTTDE HAARD JOHANNES JOSEPH WILHEDOLK EDWARDDE BRUIN RENEEVANLANDSCHOOT PETER
    • SAUNDERS MICHAEL JOHN SCOTTDE HAARD JOHANNES JOSEPH WILHELMUSDOLK EDWARDDE BRUIN RENEEVANLANDSCHOOT PETER
    • C07K16/28
    • C07K16/28C07K16/2896C07K2317/22C07K2317/569C07K2317/76
    • The present invention relates to amino acid sequences (also referred to herein as "single variable domain(s) of the invention", "Nanobody of the invention" or "Nanobodies of the invention ", ilpolypeptide(s) of the invention") that are directed against (as defined herein) members of the Notch signalling pathway such as the four mammalian members of the Notch Receptors (Notch-1, Notch-2, Notch-3, Notch-4, hereinafter also "Notch Receptors") and the five mammalian members of the Notch Ligands (the Delta-like family with "DLL1", "DLL3", "DLL4" wherein "DLL" stands for Delta-like ligand; the Jagged family with "Jagged-1", "Jagged-2", hereinafter also "Notch Ligands"), as well as to constructs that comprise or essentially consist of one or more such single variable domain(s) (also referred to herein as "construct of the invention " and "constructs of the invention", "Nanobody of the invention " or "Nanobodies of the invention",, respectively). In particular, this invention relates to Notch pathway interfering single variable domains down- or up-regulating Notch signaling (also referred to herein as "Notch-antagonists" or "Notch-agonists").
    • 本发明涉及氨基酸序列(本文中也称为“本发明的单可变结构域”,“本发明的纳米抗体”或“本发明的纳米抗体”,本发明的多聚肽“), 针对(如本文所定义)Notch信号传导途径的成员,例如Notch受体(Notch-1,Notch-2,Notch-3,Notch-4,以下也称为“Notch受体”)的四种哺乳动物成员和 Notch Ligands的五个哺乳动物成员(具有“DLL1”,“DLL3”,“DLL4”的三角形家族,其中“DLL”代表三角形配体;具有“Jagged-1”,“Jagged-2” “,以下也称为”Notch Ligands“),以及包含或基本上由一个或多个这样的单可变结构域(本文中也称为”本发明的构建体“和”本发明的构建体“)构成的构建体, ,“本发明的纳米抗体”或“本发明的纳米抗体”),特别涉及Notch 途径干扰单可变区下调或上调Notch信号传导(本文也称为“Notch拮抗剂”或“Notch-激动剂”)。